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Introduction
The relationship between elevated plasma cholesterol 
and the risk of coronary artery disease is now definitively 
established [1-5]. Accumulating evidence indicates that 
the total amount of triglyceride-rich lipoprotein particles,
i.e. chylomicron remnants, very low-density lipoproteins 
(VLDLs) and intermediate-density lipoproteins (IDLs), 
also determines the risk of developing cardiovascular 
disease [6-9]. This would explain the benefit of choles­
terol-lowering therapy observed in the majority of 
patients with coronary disease who have only marginally 
elevated plasma cholesterol levels but may exhibit other 
lipid abnormalities [4].
In patients suffering from familial combined hyper­
lipidaemia (FCH), elevated levels of triglyceride-rich 
lipoproteins mainly determine the presenting lipid 
phenotype. Because FCH appears to be the most 
common form of hyperlipidaemia in young survivors 
of myocardial infarction [10-12], causing an esti­
mated 10% of all premature coronary heart disease 
[13,14], recent research has been focused on the 
pathophysiological mechanism underlying premature 
atherogenesis in FCH. In this review, hypotheses 
concerning the metabolic and genetic basis of FCH 
and its related entities, as well as the origin of LDL 
heterogeneity associated with these lipid disorders, 
will be discussed.
Phenotypic diagnosis of FCH
In 1973, FCH was first described by Goldstein et aL [10], 
Rose et aL [13] and Nikkila and Aro [11], shortly 
followed by others [15,16], as a new autosomal dominant 
inherited lipid disorder characterized by elevated plasma 
cholesterol and triglyceride levels in first-degree relatives 
and strongly associated with premature cardiovascular
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disease. At that time, the recognition of FCH confounded 
the previously formulated Fredrickson classification of 
hyperlipoproteinaemias by the presence of first-degree 
relatives exhibiting different lipid phenotypes within one 
single family.
Because there is no specific marker for the disorder 
whereas the lipid phenotypic expression among affected 
individuals may show some variation with time, the 
diagnosis is necessarily based on family investigation 
to demonstrate a so-called ‘mixed hyperlipidaemia’ with 
either hypercholesterolaemia, hypertriglyceridaemia or 
combined hyperlipidaemia in first-degree relatives. Cri­
teria supporting the FCH diagnosis are presented in 
Table 1. Nowadays, it is common sense that all main 
inclusion criteria, in the absence of all exclusion criteria, 
should be met for a true diagnosis, whereas the diagnos­
tic value of the mentioned additional inclusion criteria is 
still under debate.
Although FCH patients frequently exhibit elevated 
plasma apo B concentrations [14,17] when compared 
with their normolipidaemic relatives, the interpretation 
of total plasma apolipoprotein B (apo B) levels as a 
diagnostic criterion is still open for discussion. A plasma 
apo B100 level above 130 mg dL_ l, standardized accord­
ing to the radioimmunoassay method of the International 
Union of Immunological Societies, may contribute to 
defining FCH patients [18,19], Considering that the lipid 
to protein ratio of VLDL and LDL particles is relatively 
constant even in FCH patients [14,20,21], total plasma 
apo B could be derived from the strong correlation that 
appears to exist between VLDL- plus LDL-cholesterol 
and plasma apo B [17]. Therefore, plasma apo B is 
strongly correlated with the presented FCH lipid pheno­
type based on elevated VLDL and/or LDL concentra­
tions [17].
For reasons that are not clear, the manifestation of 
hyperlipidaemia in childhood, as frequently observed 
in familial hypercholesterolaemia, rarely occurs in 
FCH [22]. However, hyperapobetalipoproteinaemia, a 
feature associated with FCH, has been detected in 
children of parents with premature cardiovascular 
disease [23,24].
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Table 1. Inclusion and exclusion criteria supporting the diagnosis familial combined hyperlipidaemia
Main inclusion criteria
Presence of a multiple type hyperlipidaemia in first-degree relatives of a single family comprising hypertriglyceridaemia* hypercholesterolaemia, and
combined hyperlipidaemia, as defined by fasting plasma cholesterol and/or plasma triglyceride concentrations above the 90th percentile for age and 
gender
Autosomal dominant inheritance of the hyperlipidaemia
Presence of premature atherosclerosis (before age of 60 years) in first-degree relatives 
Additional inclusion criteria
An elevated total plasma apolipoprotein-B concentration 
A LDL subfraction profile predominated by small, dense LDL particles 
Manifestation of the hyperlipidaemia in adolescence
Exclusion criteria
Presence of any form of xanthoma in first-degree relatives
Presence of a secondary cause for the hyperlipidaemia in affected relatives
Presence of the Apo e2/e2 genotype in first-degree relatives
FCH and its related lipid phenotypes
Initially FCH was thought to be inherited as a single-gene 
disorder with a major effect on triglyceride levels [10]. 
Recently, evidence for a major gene effect on triglycer­
ide levels was again provided by complex segregation 
analysis in British FCH families [25]. Although this 
supposed gene mutation has still not been located, 
other studies have indicated that a variety of metabolic 
and biochemical defects predispose for the FCH pheno­
type, suggesting that the genetic basis of this trait is 
heterogeneous and may even involve several defects in 
one family. According to these reports FCH may be 
considered more as a ‘syndrome’, showing overlapping 
characteristics with other entities (Fig. 1) such as (a) 
hyperapobetalipoproteinaemia (hyperapoB) defined by 
a normal LDL-cholesterol level with an increased LDL 
protein (apo B) content [26]; (b) the ‘atherogenic lipo­
protein phenotype’ (ALP) characterized by increased 
triglyceride and apo B levels, decreased HDL levels 
and a predominance of small, dense LDL [27]; (c)
familial dyslipidaemic hypertension (FDH), a syndrome 
of mixed lipid abnormalities resembling the FCH pheno­
type, associated with mild hypertension [28]; and (d) the 
insulin resistance syndrome, which is associated with 
increased VLDL production and impaired clearance of 
triglyceride-rich particles, also key features of FCH 
[29,30].
Pathophysiology of FCH
In general, FCH is thought to be caused by hepatic 
overproduction of VLDL with or without impaired 
clearance of triglyceride-rich lipoproteins [31,32]. As 
no single metabolic defect detected so far can fully 
account for the FCH phenotype, it has been hypothesized 
that a number of defects are involved. It still has to 
be determined whether these defects are causal of 
the disorder or are a regulatory consequence of an 
underlying metabolic defect. In general, circulating 
triglyceride-rich lipoproteins are of exogenous or endo­
genous origin. For better comprehension, these pathways 
are described in more detail below.
Hyperapobetalipoproteinaemia
Atherogenic lipoprotein pattern
Familial combined hyperlipidaemia
Figure 1. Overlapping characteristics of four entities with key 
features of the FCH phenotype, which may contribute to the complete 
picture of FCH (adapted from Kwiterovich POJ, Curr. Opin Lipidol
1993;4:133-43).
The exogenous pathway
This pathway involves the transport of dietary lipids 
from the intestine to the liver by apo B48-containing 
chylomicrons. As a result of the action of the enzyme 
lipoprotein lipase (LpL), activated by co-factor apo CII, 
fatty acids are liberated from chylomicrons and pass to 
the adipose tissue or skeletal muscle cells to be oxidized 
or stored. Reduced LpL activity as a result of LpL gene 
mutations has been reported repeatedly in subsets of FCH 
populations [33,34] and may result in impaired clearance 
of chylomicrons. For storage in adipocytes, free fatty 
acids (FFAs) are intracellularly re-esterified to triglycer­
ides, a process that is mediated by the action of a basic 
protein called acylation stimulatory protein (ASP) [35]. 
Owing to impaired ASP activity, as reported in hyper­
apoB, a reduced rate of FFA uptake into adipocytes may 
result in an increased flux of FFA to the liver and
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consequently in increased hepatic VLDL synthesis [36], 
After the release of FFAs, the remaining chylomicron 
remnant particles are taken up by the liver via a specific 
remnant receptor that only recognizes apo E as ligand
[37]. A delayed clearance of atherogenic chylomicron 
remnants, possibly due to competition between chylomi­
crons and endogenous VLDL for available LpL activity 
and competition for remnant receptor capacity, has been 
reported to exist in FCH patients [38]. In the hepatocytes, 
all components of the remnants are hydrolysed in the 
lysosomal compartment and a part of this material is 
re-used to form nascent VLDL particles entering 
the endogenous pathway. Intracellular increase in 
cholesterol in hepatocytes may increase plasma LDL- 
cholesterol concentration as a result of hepatic LDL 
receptor down-regulation.
The endogenous pathway
This pathway involves the assembly of formed endogen­
ous cholesterol and triglycerides in the core of VLDL 
followed by excretion into the circulation. In vitro studies 
show that in HepG2 cells intracellular triglyceride bio­
synthesis, but not the rate of synthesis of cholesterol or 
cholesteryl esters, determines the secretion rate of 
VLDL-apo B [39]. The triglyceride biosynthesis itself 
depends on the availability of required FFAs, which are 
either released from adipocytes, stored intrahepatically 
or converted from dietary carbohydrates [40], The 
release of required FFAs from visceral adipocytes is 
mediated by the action of the enzyme hormone-sensitive 
lipase (HSL) [41,42], Post-prandial hyperinsulinaemia 
plays a regulatory role because it inhibits the lipolytic 
effect of HSL to allow FFA uptake by adipocytes [43]. 
FCH is associated with increased insulin resistance, 
which would allow for increase in VLDL production 
by net increase of serum FFAs [44,45]. Without merging 
with lipids to allow the formation of a VLDL particle, 
nascent apoprotein B100 is degraded. This process is 
catalysed by the action of microsomal triglyceride trans­
fer protein (MTP), referring to its site of action in the 
hepatic endoplasmic reticulum [46,47], Recently, abeta- 
lipoproteinaemia, the metabolic ‘opposite5 of FCH, was 
found to be caused by MTP absence [48]. Consequently, 
it has to be established whether MTP overexpression 
could also play a role in VLDL-apo B overproduction of 
FCH.
The continuous hydrolysis of core triglycerides in 
FFAs by LpL converts VLDLs into smaller apoprotein 
B 100-containing VLDL remnants, IDL and LDL 
[40,49,50]. Recent reports suggest that a heterozygous 
state for one of the mutations found in the LpL gene, 
affecting its activity, may result in a lipoprotein pattern 
classified as FCH [33,34,51]. However, it remains 
unclear whether this phenomenon is more pronounced 
in hyperlipidaemic subjects than in normolipidaemic 
individuals without an underlying metabolic defect. 
Accurate data on the prevalence of these mutations in 
different populations may help to interpret the observed 
influences. Increased apo CIII levels are associated with
impaired clearance of triglyceride-rich lipoprotein due to 
direct inhibition of LpL by apo CIII [52]. Interestingly, 
linkage between the FCH phenotype and the AI/CIU/A1V 
gene cluster has been reported [53], However, this 
finding could not be confirmed by others, although 
several polymorphisms in the gene cluster were recently 
found to amplify the phenotypic expression in FCH [54].
A portion of small VLDL, i.e. IDL, is catabolized after 
apoprotein E-mediated binding to hepatic LDL or B/E 
receptors, which differ from the chylomicron remnant 
receptor. Affinity for the B/E receptor depends on the apo 
E isoform (i.e. high for apo E3 and E4, but low for apo 
E2). A recent study on the effects of apo E polymorphism 
on presenting lipid phenotype in FCH suggested that 
differences in apo E isoform-related clearance may 
only contribute to the hyperlipidaemia as a result of 
other defects [55]. Further hydrolysis of triglycerides, 
predominantly by hepatic triglyceride lipoprotein lipase 
(HtgL), processes remaining IDL into LDL particles that 
then mainly consist of cholesteryl esters and apoprotein 
B100 [56]. Exchange of LDL cholesteryl esters with 
VLDL triglycerides mediated by cholesteryl ester trans­
fer protein (CETP) activity determines in part the 
observed heterogeneity of LDL particles [57], as will 
be discussed later.
FCH and LDL heterogeneity
Introduction
It has been recognized for a number of years that LDL 
particles are markedly heterogeneous in physical and 
chemical properties [58-62]. In FCH, these properties of 
LDL are reported to be different from normal [20,63,64]. 
The LDL subspecies in FCH are heterogeneous with a 
propensity towards small, dense particles [14,20,65]. The 
predominance of small, dense LDL subfractions in FCH 
family members may not be fully explained by metabolic 
processing alone. Direct, as yet unclarified, genetic 
influences on the distribution are proposed as well 
[17,66,67]. Also, it is only recently that the relationship 
between qualitative features of LDL particles and cardio­
vascular disease has attracted considerable interest, This 
interest was raised by reports that certain LDL classes 
may be more atherogenic than others owing to differ­
ences in susceptibility towards oxidative modification 
[59,68-71]. Recent prospective studies supported this 
evidence of a role for small, dense LDL particles in the 
aetiology of atherosclerosis [72-74]. However, major 
questions about origin, structural variation and biological 
function of LDL subspecies are still only partly under­
stood.
Identification and characterization of LDL subfractions
Since the first reports on measurements of LDL hetero­
geneity, two basically different techniques have been 
used to identify LDL subspecies: (a) non-denaturing gel 
electrophoresis (GGE) of whole plasma or of isolated 
LDL, which separates several LDL subspecies based on
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differences in size [58]; and (b) density gradient ultra­
centrifugation (DCUG) of whole plasma, based on dif­
ferences in density within the LDL subclass population 
[75,76]. Nowadays, both techniques are widely used in 
large-scale studies to identify LDL heterogeneity.
Using GGE, most individuals are characterized by 
only two or three peaks or shoulders on the densi tome trie 
scan. Based on the location of these peaks on the gel, 
LDL subclass pattern can be classified dichotomously 
into pattern A, predominantly characterized by large 
LDL particles, and pattern B, in which small LDL 
particles predominate [27,69]. Recently, the LDL peak 
particle diameter was defined by the estimated diameter 
or size of the major observed LDL subclass, to classify 
LDL subfraction pattern in a more continuous fashion 
[77]. Single-spin DGUC procedures are designed for 
optimal resolution of prestained apo B-containing lipo­
proteins [60,62,64,78,79]. Depending on the salt gradient 
used and ultracentrifugation performed, up to 15 frac­
tions can be isolated within the LDL density of 1-019- 
l*063gmL“ 1. A single-spin DGUC procedure using 
prestained whole plasma has been the basis of the 
research in our laboratory. This method reveals up to 
five different LDL subfractions. Quantification by den- 
sitometric scanning allows the calculation of a con­
tinuous variable K describing the relative contribution 
of each LDL peak height to the total LDL [80]. In a 
comparison study, the number of LDL subfractions 
detected by GGE or DGUC was the same for more 
than 90% of the sera [81]. However, different LDL 
subfractions were less well separated by GGE than by 
DGUC. Furthermore, an advantage of the DGUC is that 
isolated samples of subclasses are available for further 
biochemical analysis. In the near future, a capillary 
electrophoretic technique may combine the advantages 
of a fast procedure and small amount of required plasma 
to discriminate between different LDL subfractions [82].
Metabolic aspects of LDL subfructions
The intravascular formation of LDL sub fractions 
involves the conversion of VLDL precursors [83,84], 
and possibly also a direct hepatic secretion of different 
IDL [85] or LDL subspecies [31,86], Previously, it was 
postulated that exchange of LDL cholesteryl ester for 
VLDL triglyceride, mediated by the CETP, results in a 
net transfer and a significant enrichment of the LDL with 
triglyceride [87-89]. The subsequent action of lipo­
protein lipase (LpL) or hepatic lipase (HtgL) results in 
hydrolysis of a significant amount of LDL triglycerides 
and thereby a decrease in particle size [90-93]. The rate 
and magnitude of exchange may depend upon the rela­
tive pool size of triglyceride-rich lipoproteins vs. the 
cholesteryl ester-rich lipoproteins. In general, this 
hypothesis of exaggerated triglyceride transfer and Hpo- 
lysis can explain the predominance of small, dense LDL 
in any form of hypertriglyceridaemia, but in FCH the 
pool of triglyceride-rich lipoproteins is primarily 
enlarged and consists of chylomicron remnants as well
[38]. However, few data, including our own, also support
the presence of a predominance of dense particles in FCH 
family members who display primarily elevated choles­
terol levels [66,67,94]. Furthermore, VLDL hetero­
geneity may also underlie LDL heterogeneity. Large 
triglyceride-rich VLDL, resembling chylomicrons in 
patients with LpL deficiency, were found to be rapidly 
removed from the circulation [50]. Several studies 
demonstrated that predominantly small VLDL particles 
secreted into the circulation are converted into LDL 
[49,95], Using stable isotopes, it was recently demon­
strated that, in subjects with predominantly dense LDL, 
both an increased production and reduced clearance of 
large VLDL occurred, which then undergo intravascular 
catabolism to successively smaller remnant particles, a 
pathway not apparent in subjects with larger, more 
buoyant LDL [96]. This and numerous other studies 
demonstrate the complexities of apo B particle metabo­
lism. However, all these studies have in common that the 
metabolic actions of lipid transfer proteins and lipases, 
eventually combined with substrate specificity as well as 
heterogeneity among apo B precursor particles, could 
account for the multiple different LDL subfractions 
observed in normal and hyperlipidaemic subjects.
Genetic aspects of LDL heterogeneity
Accumulating data suggest that the formation of LDL 
subfraction profiles is influenced genetically [97]. In 
particular, the finding of inherited LDL subfraction 
profiles in normolipidaemic families [80,98] strongly 
suggests a genetic background. Initially, Fisher et aL 
[99] reported a single genetic locus without dominance 
thought to be responsible for inheritance of LDL mole­
cular weight quality in five families. Complex segrega­
tion analysis in healthy families [98] and in families of 
probands with familial combined hyperlipidaemia [66] 
have indicated that LDL subclass pattern B, as assessed 
by gradient gel electrophoresis, is under the influence of 
a major gene or genes with a dominant or additive mode 
of inheritance. Two recent studies, a study in normo­
lipidaemic families [80] and a study in FCH families [67] 
from our laboratory, in which LDL subfractions were 
detected by DCUG, confirmed a major gene effect. In 
contrast to the previous studies of Austin et al. [66,98], 
we observed a recessive mode of inheritance and gene 
frequencies significantly different between the normo­
lipidaemic and FCH population [67,80]. However, all 
these studies, including a recently performed heritability 
analysis of a continuous LDL peak particle diameter 
performed in twins [100], have indicated that genetic 
factors could account for at least 40% of the variation in 
LDL particle size and density in both normolipidaemic 
and hyperlipidaemic subjects, with the remaining 60% 
due to non-genetic or environmental influences. Among 
these environmental factors are age, gender, body mass 
index, smoking habits, hormonal status in women (com­
bined estimated effect of 20%) and lipid and lipoprotein 
levels (estimated effect of 40%) [67,80].
Additional genetic studies have linked candidate genes 
to the small, dense LDL phenotype. Although reported
© 1997 Blackwell Science Ltd, European Journal o f  Clinical Investigation, 27, 802-811
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only once, remarkably strong linkage (LOD score of 
4*43) of pattern B to a gene locus near the LDL receptor 
on chromosome 19p was found in 51 family members of 
nine pro bands with an ‘atherogenic lipoprotein pheno­
type' (ALP), whereas weaker linkage was observed with 
the insulin receptor locus on the same chromosome 19p
[101]. Recently, in subjects of the San Antonio Heart 
Study, variations in apo E phenotype were associated not 
only with changes in the absolute LDL-cholesterol con­
centration, but also with changes in its composition
[102]. However, in 201 affected FCH subjects of our 
families, these influences of apo E polymorphism on 
LDL heterogeneity were not observed [55]. In another 
study, the apo B100 £h?RI polymorphism, previously 
associated with variation in plasma lipids, was found to 
play a role in the susceptibility to the development of 
dense LDL in viscerally obese hyperinsulinaemic men
[103]. Evidence for linkage of pattern B to three markers 
on the LDL receptor itself - the apo CIII gene on 
chromosome II, the CETP gene on chromosome L6p 
and the manganese superoxide dismutase (MnSOD) gene 
on chromosome 6q - has also been reported. However, 
no linkage was observed for other candidate loci tested; 
apo B, apo A I, apo (a), apo E/CI/CIII, LpL and HDL- 
binding protein [104,105]. Although the investigated 
genetic loci have been identified by polymorphic DNA 
markers, which do not necessarily indicate the presence 
of causative mutations, it is remarkable that the protein 
products of genes with observed linkage have con­
nections with metabolic pathways possibly involved in 
the generation or an impaired clearance of small, dense 
LDL
1 Because small, dense LDL particles have been shown, 
to have reduced affinity for the LDL receptor [106— 
108], altered LDL receptor function or regulation 
could result in further impairment of plasma clearance 
of these LDL or their metabolic products.
2 Apo CIII gene haplotypes are associated with variation 
in plasma triglyceride levels [52], which in turn could 
affect levels of small, dense LDL.
3 CETP may facilitate lipolytic conversion of larger to 
smaller LDL particles by promoting triglyceride trans­
fer into the LDL core [109].
4 A possible mechanism associated with MnSOD act- 
ivity is unclear, but it is conceivable that defective 
function of MnSOD results in increased lipid hydro­
peroxides in plasma lipoproteins, with a concomitant 
increase in oxidative susceptibility, or otherwise alters 
lipoproteins in a manner leading to formation of small, 
dense, more oxidizable LDL [71,105,110].
Although genetically influenced factors resulting in 
retardation of catabolism of triglyceride-rich lipoproteins 
or their remnants may have an aetiological or contribu­
tory role in the formation of small, dense LDL, it is 
striking that mutations in the gene coding for LpL were 
not linked to the pattern B [105] even so, because the 
LpL Asn291—»-Ser was recently found to be significantly 
linked to the presenting lipid phenotype in FCH families
[51].
Altogether, LDL heterogeneity results from a variet; 
of environmental influences and probably also fron 
direct genetic factors. In a family, one or more defect 
may be responsible for the major gene and additiv< 
effects identified by segregation analysis.
FCH and premature atherogenesis
In spite of often mildly elevated lipid levels comparec 
with other lipid disorders, a high prevalence of cardio­
vascular diseases occurs in FCH families. The explana­
tion for premature cardiovascular disease in FCH may be 
attributed to the increased prevalence of small, dense
LDL [27,111].
One of the earliest events in the formation of athero­
sclerotic plaques is the massive accumulation of choles­
terol in so-called scavenger cells to convert into foam 
cells in the artery wall [112,113]. As normal receptor- 
mediated endocytosis of cholesterol via the LDL receptor 
initiates intracellular processes that prevent further LDL 
uptake, alternative mechanisms are necessary to explain 
the foregoing intracellular cholesterol accumulation 
[114], Many lines of evidence support the hypothesis 
that oxidative modification of LDL plays a pivotal role in 
atherogenesis [115-118]. However, this theory cannot be 
considered proven for the human disease [119]. The 
oxidative modification hypothesis proposes that oxi­
dative damage to LDL generates a series of modified 
forms of LDL (oxLDL) that are in a number of ways 
more atherogenic than native LDL. In contrast to native 
LDL, oxidized LDL (oxLDL) is recognized and rapidly 
internalized by macrophage scavenger receptors [115], 
exhibits marked effects on the viability of endothelial 
cells and smooth muscle cells and alters the chemotactic 
activity of monocytes and monocyte-derived macro­
phages, all features which have been implicated in 
atherogenesis [115]. Special oxLDL receptors on the 
macrophages may not be down-regulated by the endo­
cytosis of several forms of modified LDL and facilitate 
intracellular accumulation of oxLDL [120-123]. Small, 
dense LDL, being more susceptible to oxidative modi­
fication [64,71,124], may increase the supply of oxLDL 
to these receptors. Recently, in subjects with FCH, total 
LDL was found to be more prone to in vitro oxidation 
owing to the predominance of dense LDL particles. In 
addition, it was suggested that the decreased redox status 
of coenzyme Q10 in LDL from subjects with a dense 
LDL subfraction profile reflected the presence of already 
in vivo modified LDL owing to lipid peroxidation in the 
circulation [125,126].
Therapeutic options in FCH
Because of the up to 10-fold increased incidence of 
cardiovascular diseases in FCH patients [10,14], family 
screening and lipid-lowering treatment should be initiated. 
Both lowering of the total amount of atherogenic lipo­
proteins, i.e. LDL-cholesterol and triglyceride-rich lipo­
proteins, as well as a reduction in the atherogenicity of 
LDL, i.e. reduction in the total amount of small, dense
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LDL particles, should be aimed at. For this puipose, diet 
and lifestyle changes are usually insufficient and, con­
sequently, drug therapy is frequently indicated. In the last 
decade, a spectrum of effective lipid-lowering drugs 
became available. The HMG-CoA reductase inhibitors 
are highly effective in reducing LDL-cholesterol in 
patients with primary hypercholesterolaemia [127]. 
Although these drugs show some triglyceride reduction 
as well, less effect is observed in reduction of the amount 
of small, dense LDL particles [19,128,129]. Fibrates 
show a primary triglyceride-lowering effect [130]. Con­
vincingly related to this effect on triglyceride levels, a 
reduction in the size of the small, dense LDL subfraction 
and normalization of the LDL subfraction profile is 
observed, whereas the total amount of LDL-cholesterol 
is unaffected or may even increase [19,131,132]. Nico­
tinic acid, which especially reduces triglyceride levels by 
modifying the amount of FFA entering the liver, can be 
very useful in FCH [3,133,134], However, because of 
several side-effects it is prescribed less often in Europe. 
Bile acid-binding resins are frequently contraindicated in 
FCH because of an increase in VLDL concentration 
[135,136]. The place of antioxidants, i.e. vitamins E 
and C, /3-carotene and flavonoids, to prevent LDL par­
ticles from oxidative modification and cardiovascular 
disease is still under investigation. Although a reduction 
in in vitro LDL oxidizability has been observed [137- 
140] and a reduced risk of coronary heart disease was 
found [141-146], the results of these studies are not 
totally consistent.
A direct comparison of the HMG-CoA reductase 
inhibitor simvastatin and the fibrate gemfibrozil in the 
treatment of FCH subjects with a combined hyper­
lipidaemic phenotype demonstrated the specific effect 
of both drugs. However, none of these agents alone 
completely normalized the lipid and lipoprotein profiles. 
Interestingly, an overall dense LDL sub fraction profile, 
although less pronounced, persisted despite substantial 
triglyceride-lowering [19]. This finding therefore sup­
ports the hypothesis of small, dense LDL being present in 
FCH subjects irrespective of metabolic influences.
So far, the use of drugs should be based on which 
lipoprotein fraction is elevated the most, and probably a 
combination of a statin and a fibrate may be the therapy 
of choice in selected FCH patients with a high risk of 
cardiovascular disease. In future, possibly more potent 
HMG-CoA reductase inhibitors, such as atorvastatin, 
which also have a strong triglyceride-lowering effect, 
may become the drug of choice [147,148].
Conclusion
Because of its large impact on total cardiovascular 
mortality, knowledge of the pathogenesis of the hetero­
geneous FCH syndrome as well as the cause of the 
associated premature atherogenesis is essential. A 
major difficulty arises in identifying affected subjects, 
because a specific marker for the disorder is still lacking. 
Therefore, family investigation should be performed 
to verify the diagnosis in a patient with combined
hyperlipidaemia and/or premature cardiovascular dis­
ease. Until now, this is the only way to prevent affected 
relatives from premature cardiovascular disease.
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